<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6566">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01932203</url>
  </required_header>
  <id_info>
    <org_study_id>20130006</org_study_id>
    <nct_id>NCT01932203</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Cilostazol and Aspirin on Cerebral Small Vessel Disease</brief_title>
  <acronym>Challenge</acronym>
  <official_title>A Multicenter, Randomized, Double Blind Study to Compare the Efficacy Between Cilostazol and Aspirin on White Matter Changes by Cerebral Small Vessel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inha University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Inha University Hospital</source>
  <oversight_info>
    <authority>South Korea: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There may be a difference in efficacy of cilostazol and aspirin on progression of white
      matter changes in cerebal small vessel disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to compare the efficacy of aspirin and cilostazol on
      volume of white matter changes in cerebral small vessel disease.

      The secondary objectives are to compare the impact of aspirin and cilostazol on DTI
      parameters, lacune, microbleeds, brain atrophy, cognition, depression, neurologic signs,
      gait, urination, and activities of daily living.

      We also investigate risk factors associated with progression of cerebral small vessel
      disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Volume of white matter changes (WMCs)</measure>
    <time_frame>baseline, week 104</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean diffusivity and Fraction Anisotrophy on Diffusion Tensor Imaging</measure>
    <time_frame>baseline and week 104</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of lacunes</measure>
    <time_frame>baseline and week 104</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of microbleeds</measure>
    <time_frame>baseline and week 104</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>brain volume and cortical thickness</measure>
    <time_frame>baseline and week 104</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini-Mental State Examination</measure>
    <time_frame>baseline, week 52, and week 104</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive test</measure>
    <time_frame>baseline, week 52, and week 104</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seoul Verbal Learning Test, Boston Naming test-short form, ROCF copy, animal fluency, phonemic fluency, Stroop test, Digit-symbol test, Trail making test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Dementia Rating scale</measure>
    <time_frame>baseline, week 52, and week 104</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>King's Health Questionnaire</measure>
    <time_frame>baseline, week 42, and week 104</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geriatric Depression Scale-Short form</measure>
    <time_frame>baseline, week 52, and week 104</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caregiver-Administered Neuropsychiatric Inventory (CGA-NPI)</measure>
    <time_frame>baseline, week 52, and week 104</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bayer Activities of Daily Living</measure>
    <time_frame>baseline, week 52, and week 104</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index</measure>
    <time_frame>baseline, week 52, and week 104</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pyramidal and Extrapyramidal Scale (PEPS)</measure>
    <time_frame>baseline, week 52, and week 104</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timed UP and Go (TUG) test</measure>
    <time_frame>baslien, week 52, and week 104</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event</measure>
    <time_frame>baseline, week 4, 16, 28, 40, 52, 64, 76, 88, and 104</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>vWF, TF, ICAM-1, VCAM-1, IL-6, IL-18, hsCRP, APOE genotyping, RAS gene polymorphism</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>BUN, creatinine, hemoglobin, platelet, GOT, GPT, albumin, HbA1C, glucose, LDL-C, HDL-C, triglyceride, total cholesterol, uric acid, albumin(micro, random urine)/creatinine ratio</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">238</enrollment>
  <condition>Cerebral Small Vessel Disease</condition>
  <arm_group>
    <arm_group_label>aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>aspirin 100mg by mouth once a day for 104 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cilostazol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pletaal SR 200mg  by mouth once a day for 104 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin</intervention_name>
    <description>100mg once a day</description>
    <arm_group_label>aspirin</arm_group_label>
    <other_name>aspirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cilostazol</intervention_name>
    <description>200mg once a day</description>
    <arm_group_label>Cilostazol</arm_group_label>
    <other_name>Pletaal SR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  50 to 85 years of age

          -  He/She can walk to the hospital (walker or cane is permissible).

          -  Cerebral small vessel disease is oberved on brain MRI.

             1) presence of one or more lacunar infarction and 2) moderate or severe confluenct
             leukoaraiosis (defined as grade 2 or 3 on a modified Fazekas scale): periventricular
             WMCs with cap or rims lager than 5mm and deep subcortical WMCs &gt;10 mm in maximum
             diameter

          -  written informed consent

        Exclusion Criteria:

          -  Any patient with contraindication of antiplatelets

          -  Any patient with cardioembolic source

          -  Carotid bruit or large cerebral artery stenosis &gt;50%

          -  Cortical infarction or subcortical infarction lager than 1.5 cm

          -  bleeding tendency

          -  chronic liver disease (AST or ALT &gt;100 IL/L)

          -  chronic renal disease (Creatinine &gt;3.0mg/dL)

          -  active gastrointestinal ulcer

          -  any patients with any severe or unstable medical disease that may prevent them from
             completing study requirements (i.e., unstable or severe asthma)

          -  Anemia (Hb &lt;10g/dL) or thrombocytopenia

          -  Cardiac pacemaker or contraindication to MRI

          -  Pregnancy or breast-feeding

          -  drug or alcohol addiction

          -  Any other white matte disease (i.e., Multiple sclerosis, sarcoidosis, or brain
             irradiation, etc) or brain tumor

          -  Parkinson's disease, Alzheimer's disease or any other neurodegenerative disease

          -  any hearing or visual impairment that can disturb the efficient evaluation of the
             patient

          -  recent cerebral infarction with 3 months
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seong H. Choi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inha University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seong H. Choi, MD, PhD</last_name>
    <phone>82 32 890 3659</phone>
    <email>seonghye@inha..ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jina Lee, RA</last_name>
    <phone>82 32 890 1128</phone>
    <email>llkanonll@naver.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hallym University Medical Center</name>
      <address>
        <city>Anyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mi S. Oh, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mi S. Oh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang University Bucheon Hospital</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sun A. Park, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sun A. Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bucheon St.Mary's Hospital</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yong S. Shim, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yong S. Shim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Konyang University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bora Yoon, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bora Yoon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Byeong C. Kim, MD</last_name>
    </contact>
    <investigator>
      <last_name>Byeong C. Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <zip>400-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seong H Choi, MD, PhD</last_name>
      <phone>82 32 890 3659</phone>
      <email>seonghye@inha.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Seong H. Choi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kee H. Park, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kee H. Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eun-Joo Kim, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eun-Joo Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kyung W. Park, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kyung W. Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ewha Womans University Mokdong Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jee H. Jeong, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jee H. Jeong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chungang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Young-Chul Yoon, MD</last_name>
    </contact>
    <investigator>
      <last_name>Young-Chul Yoon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Key C Park, MD</last_name>
    </contact>
    <investigator>
      <last_name>Key C. Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jae-Hong Lee, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jae-Hong Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Duk L. Na, MD</last_name>
    </contact>
    <investigator>
      <last_name>Duk L. Na, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dong-Won Yang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Dong-Won Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>So Y. Moon, MD</last_name>
    </contact>
    <investigator>
      <last_name>So Y. Moon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 12, 2013</lastchanged_date>
  <firstreceived_date>August 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Inha University Hospital</investigator_affiliation>
    <investigator_full_name>Inha University Hospital</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Cerebral small vessel disease</keyword>
  <keyword>Leukoaraiosis</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <keyword>Diffusion Tensor Imaging</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Cilostazol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
